2020

August
Highlighted Articles
- Rain Therapeutics signs license agreement with Drexel
  
  August 25, 2020
  
  Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announces the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of RAD52, a critical molecule involved in the DNA damage response (DDR) pathway. The agreement expands Rain’s targeted oncology pipeline to include synthetic lethal strategies for the treatment of cancers associated with mutations in the DDR pathway, including breast and ovarian cancers characterized by BRCA1/2 mutations.
  
  Read More
- Alex Mazin wins DOD and NIH grants totaling $2.844 Million to support his development of Inhibitors of RAD52 as a Therapy Against BRCA-Deficient cancers
  
  August 1, 2020
  
  Alex Mazin wins DOD and NIH grants totaling $2.844 Million to support his development of Inhibitors of RAD52 as a Therapy Against BRCA-Deficient cancers.
  
  Read More
June
Highlighted Articles
- Kinos Medical Receives 501(k) Substantially Equivalent Determination for their Axiom Total Ankle Replacement Device from the FDA
  
  June 30, 2020
  
  Congratulations to Kinos Medical who received their 501(k) Substantially equivalent determination for their Axiom Total Ankle Sytem from the FDA.
  
  Read More
- Drexel Takes Top Spot on National Rankings for Innovation
  
  June 26, 2020
  A new report from the George W. Bush Institute and the innovation consulting firm Opus Faveo Innovation Development named Drexel the most innovative mid-sized research university in the country.
  Read More
- Sandhya Kortagere Wins 2020 Equalize Therapeutic Award
  
  June 25, 2020
  
  Read More
March
Highlighted Articles
- Coulter Awardee Wins Distinguished Drexel 40 Under 40 Award
  
  March 18, 2020
  
  Read More